Literature DB >> 8567023

Hexachlorobenzene treatment increases the number of splenic B-1-like cells and serum autoantibody levels in the rat.

P Schielen1, W Van Rodijnen, R H Pieters, W Seinen.   

Abstract

In the present study, the role of B-1 cells in hexachlorobenzene (HCB)-induced autoimmune aberrations in the Wistar rat was investigated. To that end, male and female rats were exposed to a semi-synthetic diet containing 0 or 1000 mg HCB/kg food for 3 weeks. After dissection, serum was prepared form coagulated blood to determine (auto)antibody levels, and spleens and lymph nodes were isolated and weighed. Cell suspensions were prepared, counted and analysed for B- and T-cell subsets by flow cytometry. Quantification of antibody-secreting cells (ASC) in spleen cell suspensions was done with an ELISPOT assay. Previous findings that HCB treatment induced an increase of relative lymph node and spleen weights and serum (auto)antibody levels were confirmed, while it appeared that numbers of some lymph nodal, and of the splenic large cell populations, were elevated as well. HCB treatment did not change subsets of lymph nodal T and B cells, but elevated the absolute numbers of large splenic CD4+ T cells by about 70%, IgMdull/IgDbright B cells by about 60%, and IgMbright/IgDdull B cells by about 200% cells of control numbers, and the absolute numbers of splenic IgM and IgG (auto) ASC by 300-400% of the control numbers. As splenic IgMbright/IgDdull numbers and ASC numbers correlated with statistical significance, the results indicate that HCB treatment selectively activates rat splenic B-1 cells, which may underlie the elevation of serum autoantibody levels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8567023      PMCID: PMC1384057     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  16 in total

Review 1.  CD5 B cells in autoimmunity.

Authors:  N Talal; M Dauphinee; S A Ahmed
Journal:  Ann N Y Acad Sci       Date:  1992-05-04       Impact factor: 5.691

Review 2.  The development and repertoire of B-1 cells (CD5 B cells).

Authors:  A B Kantor
Journal:  Immunol Today       Date:  1991-11

Review 3.  Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'.

Authors:  S Avrameas
Journal:  Immunol Today       Date:  1991-05

Review 4.  Drug-related lupus. Incidence, mechanisms and clinical implications.

Authors:  L E Adams; E V Hess
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

5.  Estrogen induces normal murine CD5+ B cells to produce autoantibodies.

Authors:  S Ansar Ahmed; M J Dauphinée; A I Montoya; N Talal
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

6.  Turkish epidemic hexachlorobenzene porphyria. A 30-year study.

Authors:  H Peters; D Cripps; A Göcmen; G Bryan; E Ertürk; C Morris
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

Review 7.  Drug and environmental effects on the induction of autoimmunity.

Authors:  A B Mongey; E V Hess
Journal:  J Lab Clin Med       Date:  1993-12

8.  Hexachlorobenzene-induced stimulation of the humoral immune response in rats.

Authors:  J G Vos; M J van Logten; J G Kreeftenberg; W Kruizinga
Journal:  Ann N Y Acad Sci       Date:  1979-05-31       Impact factor: 5.691

9.  Autoimmune effects of hexachlorobenzene in the rat.

Authors:  P Schielen; W Schoo; J Tekstra; H H Oostermeijer; W Seinen; N Bloksma
Journal:  Toxicol Appl Pharmacol       Date:  1993-10       Impact factor: 4.219

10.  Two subsets of rat T lymphocytes defined with monoclonal antibodies.

Authors:  R J Brideau; P B Carter; W R McMaster; D W Mason; A F Williams
Journal:  Eur J Immunol       Date:  1980-08       Impact factor: 5.532

View more
  1 in total

1.  Associations of blood levels of PCB, HCHS, and HCB with numbers of lymphocyte subpopulations, in vitro lymphocyte response, plasma cytokine levels, and immunoglobulin autoantibodies.

Authors:  V Daniel; W Huber; K Bauer; C Suesal; C Conradt; G Opelz
Journal:  Environ Health Perspect       Date:  2001-02       Impact factor: 9.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.